11 September

S01: Human biomonitoring – a view to the future based on current achievements

人类生物监测--基于现有进展的未来瞻望

S03: Current and future perspectives on the extended one-generation reproductive toxicity study (EOGRTS)

耽搁一代生殖毒性检测（EOGRTS）确当前情况与未来瞻望

S05: Consideration of the endogenous exposome in risk assessment

风险评估中对内源性露出体成分的思考

S07: Involvement of mitochondria in adverse drug reactions

线粒体参加药物不良反映

S09: Current use of NAMS/alternatives in DART testing

目前在 DART 测试中使用的NAMS/代替步骤

S11: Contact allergen potency: the missing piece in the huge puzzle of alternative methods

接触过敏原效力：代替步骤的巨大难题中缺失的一环

S12: Finding synergies for 3Rs – toxicokinetics, physiologically-based kinetic (PBK) models and read-across

寻找 3R 的协同作用--毒代动力学、基于生理学的动力学 (PBK) 模型和读数交叉

12 September

S13: Acceptance and use of in vitro methods: a perspective from various chemical sectors

体表步骤的利用：来自分歧化学领域的视角

S14: NAM mechanistic information for the risk assessment of chemical mixtures

用于化学混合物风险评估的NAM机理信息

S15: Next generation risk assessment of food chemicals, environmental contaminants and pharmaceuticals using open-source modelling platforms: perspectives from regulatory agencies, academia and industry

利用开源建模平台对食品化学品、环境传染物和药品进行下一代风险评估：来自监管机构、学术界和工业界的概想

S16: Organ-on-a-chip and the developing role in early drug development

器官芯片和在早期药物开发中阐扬的作用

S17: Critical organs and exposure windows for developmental immunotoxicity assessment

发育期免疫毒性评估的关键器官和露出窗口

S20: Are diseases and conditions related to hormone imbalance really increasing?

与荷尔蒙失调有关的疾病和病症真的在增长吗？

S21: Environmental chemical mixtures and cancer hallmarks – new developments and open questions

环境化学混合物和癌症标志--新进展和未决问题

S22: Role of immunity and contribution of immunotoxicity in the identification of non-genotoxic carcinogens

免疫的作用和免疫毒性在确定非遗传毒性致癌物中的贡献